Nchi: Marekani
Lugha: Kiingereza
Chanzo: NLM (National Library of Medicine)
GEMFIBROZIL (UNII: Q8X02027X3) (GEMFIBROZIL - UNII:Q8X02027X3)
Contract Pharmacy Services-PA
GEMFIBROZIL
GEMFIBROZIL 600 mg
ORAL
PRESCRIPTION DRUG
Gemfibrozil tablets are indicated as adjunctive therapy to diet for: - Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying
Gemfibrozil tablets USP, 600 mg are available as white, oval, film-coated tablets scored on one side, debossed "225"-"I/G" on the scored side. Store at 20º to 25ºC (68º to 77ºF) [See USP Controlled Room Temperature]. Protect from light and humidity. Dispense contents in a tight container as defined in the USP, with a child-resistant closure (as required). Manufactured By: Camber Pharmaceuticals Piscataway, NJ 08854 Repackaged by: Contract Pharmacy Services-PA 125 Titus Ave Suite 200 Warrington, PA 18976 USA Original--11/2010--NJW
Abbreviated New Drug Application
GEMFIBROZIL- GEMFIBROZIL TABLET, FILM COATED CONTRACT PHARMACY SERVICES-PA ---------- GEMFIBROZIL TABLETS USP, 600 MG RX ONLY DESCRIPTION Gemfibrozil is a lipid regulating agent. It is available as tablets for oral administration. Each tablet contains 600 mg gemfibrozil. In addition, each tablet contains the following inactive ingredients: calcium stearate, colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose, microcrystalline cellulose, polydextrose K, polyethylene glycol 4000, polysorbate 80, pregelatinized starch and titanium dioxide. The chemical name is 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid, with the following structural formula: C H O M.W. 250.35 The solubility in water and acid is 0.0019% and in dilute base it is greater than 1%. The melting point is 58 to 61 C. Gemfibrozil is a white solid which is stable under ordinary conditions. CLINICAL PHARMACOLOGY Gemfibrozil is a lipid regulating agent which decreases serum triglycerides and very low density lipoprotein (VLDL) cholesterol, and increases high density lipoprotein (HDL) cholesterol. While modest decreases in total and low density lipoprotein (LDL) cholesterol may be observed with gemfibrozil therapy, treatment of patients with elevated triglycerides due to Type IV hyperlipoproteinemia often results in a rise in LDL-cholesterol. LDL-cholesterol levels in Type IIb patients with elevations of both serum LDL-cholesterol and triglycerides are, in general, minimally affected by gemfibrozil treatment; however, gemfibrozil usually raises HDL-cholesterol significantly in this group. Gemfibrozil increases levels of high density lipoprotein (HDL) subfractions HDL and HDL , as well as apolipoproteins AI and AII. Epidemiological studies have shown that both low HDL- cholesterol and high LDL-cholesterol are independent risk factors for coronary heart disease. In the primary prevention component of the Helsinki Heart Study, in which 4081 male patients between the ages of 40 and 55 were studied in a randomized, double-blind, placebo-controlle Soma hati kamili